37 C.F.R. § app G to Subpart G of Part 1
Current through July 31, 2024
| Numeric identifier | Definition | Comments and format | Mandatory (M) or optional (O) |
| [LESS THAN]110[GREATER THAN] | Applicant | If Applicant is inventor, then preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials | M. |
| [LESS THAN]120[GREATER THAN] | Title of Invention | M. | |
| [LESS THAN]130[GREATER THAN] | File Reference | Personal file reference | M when filed prior to assignment or appl. number. |
| [LESS THAN]140[GREATER THAN] | Current Application Number | Specify as: US 09/999,999 or PCT/US09/99999 | M, if available. |
| [LESS THAN]141[GREATER THAN] | Current Filing Date | Specify as: yyyy-mm-dd | M, if available. |
| [LESS THAN]150[GREATER THAN] | Prior Application Number | Specify as: US 09/999,999 or PCT/US09/99999 | M, if applicable include priority documents under 35 U.S.C. 119 and 120 . |
| [LESS THAN]151[GREATER THAN] | Prior Application Filing Date | Specify as: yyyy-mm-dd | M, if applicable. |
| [LESS THAN]160[GREATER THAN] | Number of SEQ ID NOs | Count includes total number of SEQ ID NOs | M. |
| [LESS THAN]170[GREATER THAN] | Software | Name of software used to create the "Sequence Listing" | O. |
| [LESS THAN]210[GREATER THAN] | SEQ ID NO:#: | Response shall be an integer representing the SEQ ID NO shown | M. |
| [LESS THAN]211[GREATER THAN] | Length | Respond with an integer expressing the number of bases or amino acid residues | M. |
| [LESS THAN]212[GREATER THAN] | Type | Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the [LESS THAN]220[GREATER THAN] to [LESS THAN]223[GREATER THAN] feature section | M. |
| [LESS THAN]213[GREATER THAN] | Organism | Scientific name, i.e., Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the [LESS THAN]220[GREATER THAN] to [LESS THAN]223[GREATER THAN] feature section | M. |
| [LESS THAN]220[GREATER THAN] | Feature | Leave blank after [LESS THAN]220[GREATER THAN]. [LESS THAN]221-223[GREATER THAN] provide for a description of points of biological significance in the sequence | M, under the following conditions: If "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. |
| [LESS THAN]221[GREATER THAN] | Name/Key | Provide appropriate identifier for feature, from WIPO Standard ST.25 (2009), Appendices E and F to this subpart | M, under the following conditions: If "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence. |
| [LESS THAN]222[GREATER THAN] | Location | Specify location within sequence; where appropriate, state number of first and last bases/amino acids in feature | M, under the following conditions: If "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence. |
| [LESS THAN]223[GREATER THAN] | Other Information | Other relevant information; four lines maximum | M, under the following conditions: If "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA. |
| [LESS THAN]300[GREATER THAN] | Publication Information | Leave blank after [LESS THAN]30[GREATER THAN] | O. |
| [LESS THAN]301[GREATER THAN] | Authors | Preferably max. of 10 named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials | O. |
| [LESS THAN]302[GREATER THAN] | Title | O. | |
| [LESS THAN]303[GREATER THAN] | Journal | O. | |
| [LESS THAN]304[GREATER THAN] | Volume | O. | |
| [LESS THAN]305[GREATER THAN] | Issue | O. | |
| [LESS THAN]306[GREATER THAN] | Pages | O. | |
| [LESS THAN]307[GREATER THAN] | Date | Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy | O. |
| [LESS THAN]308[GREATER THAN] | Database Accession Number | Accession number assigned by database, including database name | O. |
| [LESS THAN]309[GREATER THAN] | Database Entry Date | Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy | O. |
| [LESS THAN]310[GREATER THAN] | Patent Document Number | Document number; for patent-type citations only. Specify as, for example, US 09/999,999 | O. |
| [LESS THAN]311[GREATER THAN] | Patent Filing Date | Document filing date, for patent-type citations only; specify as yyyy-mm-dd | O. |
| [LESS THAN]312[GREATER THAN] | Publication Date | Document publication date, for patent-type citations only; specify as yyyy-mm-dd | O. |
| [LESS THAN]313[GREATER THAN] | Relevant Residues | FROM (position) TO (position) | O. |
| [LESS THAN]400[GREATER THAN] | Sequence | SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence | M. |
37 C.F.R. app G to Subpart G of Part 1
Part 2 is placed in the separate grouping of parts pertaining to trademarks regulations.
Part 6 is placed in the separate grouping of parts pertaining to trademarks regulations.
Part 7 is placed in the separate grouping of parts pertaining to trademarks regulations.
Part 1 is placed in the separate grouping of parts pertaining to patents regulations.
Part 3 pertaining to both patents and trademarks is placed in the grouping pertaining to patents regulations.
Part 4 is placed in the separate grouping of parts pertaining to patents regulations.
Part 5 is placed in the separate grouping of parts pertaining to patents regulations.